ARCT Share Price Performance
US$0
-18.05 (-100.00%)
Price US$0
Fair ValueUS$30.00
Share Pricen/a
New Narrative • Sep 08
Arcturus Therapeutics Holdings Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 86 Fair Values set on narratives written by author
ARCT Community Narratives
BI
Fair Value
·Fair Value US$30 43.6% undervalued intrinsic discount
Arcturus Therapeutics: Strategic opportunities beyond CSL
1users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$22.3 24.1% undervalued intrinsic discount
Rare Disease Pipeline And sa mRNA Vaccine Platform Will Reshape Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$8 111.6% overvalued intrinsic discount
Revenues Will Fall And Pipeline Risks Will Hinder RNA Upside
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Arcturus Therapeutics Holdings
43.6% undervalued intrinsic discount
Arcturus Therapeutics: Strategic opportunities beyond CSL
View narrativeBI
Published 22 May
Arcturus Therapeutics Holdings
24.1% undervalued intrinsic discount
Rare Disease Pipeline And sa mRNA Vaccine Platform Will Reshape Long Term Outlook
View narrativeAN
Published 8 Sep
Arcturus Therapeutics Holdings
54.8% undervalued intrinsic discount
Self-amplifying mRNA Will Meet Aging Global Therapy Demand
View narrativeAN
Updated 30 Jun
Arcturus Therapeutics Holdings
111.6% overvalued intrinsic discount
Revenues Will Fall And Pipeline Risks Will Hinder RNA Upside
View narrativeAN
Updated 16 Jun
Trending Discussion
No trending discussion available.
Recently Updated Narratives
BI
Arcturus Therapeutics: Strategic opportunities beyond CSL
Fair Value: US$30 43.6% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rare Disease Pipeline And sa mRNA Vaccine Platform Will Reshape Long Term Outlook
Fair Value: US$22.3 24.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ARCT: Index Removals And New CFO Appointment Will Support Future Upside
Fair Value: US$37.46 54.8% undervalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Arcturus Therapeutics Holdings Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -3.28
- -195.50%
- -317.61%
- 0%
About ARCT
- Founded
- 2013
- Employees
- 109
- CEO
- WebsiteView website
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
